Editas Medicine (EDIT) Long-Term Investments (2020 - 2024)

Editas Medicine (EDIT) has 5 years of Long-Term Investments data on file, last reported at $39.2 million in Q2 2024.

• Quarterly Long-Term Investments fell 18.45% year-over-year to $39.2 million in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $39.2 million (down 18.45% YoY) and the FY2023 annual result came in at $104.0 million, up 11.74% from the prior year.
• Long-Term Investments declined to $39.2 million in Q2 2024 per EDIT's latest filing, from $80.6 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $120.1 million in Q4 2021 and bottomed at $39.2 million in Q2 2024.
• The 5-year median for Long-Term Investments is $85.4 million (2021), against an average of $82.3 million.
• The widest annual swing landed in 2021, when Long-Term Investments surged 115.65%; it then sank 40.68% in 2022.
• Tracing EDIT's Long-Term Investments over 5 years: stood at $109.7 million in 2020, then increased by 9.49% to $120.1 million in 2021, then decreased by 22.47% to $93.1 million in 2022, then grew by 11.74% to $104.0 million in 2023, then sank by 62.32% to $39.2 million in 2024.
• Per Business Quant, the three latest EDIT Long-Term Investments figures stand at $39.2 million (Q2 2024), $80.6 million (Q1 2024), and $104.0 million (Q4 2023).

Peer Comparison